Mereo BioPharma Group plc Board of Directors

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

Dr. Denise Vera Scots-Knight Ph.D.

Dr. Denise Vera Scots-Knight Ph.D.

Co-Founder, CEO & Executive Director

Ms. Christine Fox CPA

Ms. Christine Fox CPA

Chief Financial Officer

Ms. Alexandra Hughes-Wilson

Ms. Alexandra Hughes-Wilson

Chief of Patient Access & Commercial Planning

Mr. Bo Kara

Mr. Bo Kara

Senior VP and Head of Pharmaceutical Development & CMC

Dr. Jackie Parkin

Dr. Jackie Parkin

Senior VP & Therapeutic Head

Dr. John P. Richard M.B.A.

Dr. John P. Richard M.B.A.

Co-Founder & Chief Business Officer

Dr. Suba Krishnan

Dr. Suba Krishnan

Senior Vice President of Clinical Development

Mr. Charles Edward Sermon

Mr. Charles Edward Sermon

Co-Founder, General Counsel, Business Development & Company Secretary

Dr. John A. Lewicki Ph.D.

Dr. John A. Lewicki Ph.D.

Chief Scientific Officer

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.